Section
A Phase 2 trial of eltrekibart, a novel monoclonal antibody targeting CXCR1/2 ligands, suggests high clinical efficacy in hidradenitis suppurativa. While frequentist analysis was neutral, Bayesian augmented models showed a 99.9% probability
This report examines a clinical trial using 30-minute daily saturated saline immersion to treat refractory plantar warts, achieving an 88.2% complete remission rate without pain or recurrence.
The Phase 3 DISCREET trial demonstrates that apremilast provides sustained clinical efficacy and quality-of-life improvements for patients with moderate to severe genital psoriasis over 32 weeks, offering a viable oral alternative for a tra
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
A pragmatic RCT comparing weekly versus daily bathing in 438 eczema patients found no significant difference in symptom severity, supporting patient autonomy in choosing hygiene routines.
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.
This systematic review and meta-analysis evaluates 15 HS-specific PROMs using the COSMIN framework, identifying 7 recommended instruments and highlighting the superior psychometric performance of HiSQOL-17 while uncovering significant gaps
Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enablin
This review synthesizes findings from the CLEAN-IT trial and historical data to evaluate the impact of chlorhexidine bathing on nosocomial infections, MDR pathogens, and reserve antibiotic consumption in critically ill patients.
The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab
Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient
The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are
The BE RADIANT trial demonstrates that bimekizumab provides rapid, superior, and durable skin clearance (PASI 100) and symptom relief compared to secukinumab over three years, with a manageable safety profile and significant quality-of-life
The RESMAIN trial demonstrates that resminostat maintenance therapy doubles median progression-free survival in patients with advanced mycosis fungoides or Sézary syndrome, offering a potential new standard for managing patients who have ac
A systematic review of 1,802 patients reveals that COL7A1 variant type and location, particularly premature termination codons and NC1 domain involvement, are definitive predictors of clinical severity and systemic complications in recessiv
A large-scale study within the VA health system identifies Agent Orange exposure as a significant risk factor for acral melanoma, while highlighting distinct clinical profiles and a paradoxical inverse association with smoking compared to o
The final 9-year analysis of the CheckMate 238 trial confirms that adjuvant nivolumab provides a sustained recurrence-free survival advantage over ipilimumab in patients with resected high-risk melanoma, with 44% of patients remaining recur
Researchers have developed a novel P/G@IYCe dressing combining yolk immunoglobulins and cerium oxide nanoparticles. This synergy effectively neutralizes bacterial pathogens and reactive oxygen species, facilitating rapid, high-quality skin
